Green Check Named to 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
August 12, 2025
High Tide Provides Corporate Updates
August 12, 2025
[PRESS RELEASE] – EDMONTON, Alberta, Aug. 12, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the launch of Whistler Cannabis Co. in Australia. As one of Canada’s original cannabis brands, with a proud history of growing premium, indoor craft cannabis, this unique brand offers Australian patients a true Canadian cannabis experience.
“Whistler is a tried-and-true brand in the Canadian market,” said Andre Jerome, executive vice president of global business development at Aurora. “We’re excited to now extend its legacy, and our Canadian cultivation expertise, to Australian patients. This milestone underscores our commitment to global growth and our patient-first approach.”
First developed in 2013, Whistler is cultivated in Aurora’s state-of-the-art facility, Aurora Alpine, located in Pemberton Valley, British Columbia. Produced in small batches using top-tier, proprietary genetics, each plant is harvested at its peak, ensuring consistent quality. The premium craft medical cannabis flower is hang-dried and hand-trimmed, undergoing a slow, controlled drying process to preserve delicate trichomes, which contain most of the plant’s aroma, cannabinoids and active compounds.
The first two Whistler Cannabis Co. products to launch in Australia are:
- Ginger Breath – 32% THC, Indica, 10g, bred from ’91 Royale and Driftwood Diesel genetics, and has a terpene profile of Caryophyllene, Pinene and Linalool. This cultivar has a complex aroma profile of spicy-ginger, gasoline, chai and citrus.
- Critical Diesel – 28% THC, Sativa, 10g, bred from Critical Sensi Star and Driftwood Diesel lineages, and has a terpene profile of Caryophyllene, Pinene and Myrcene. This cultivar has a fruity aroma profile of cherry, grape, strawberry, vanilla and gasoline.
Aurora has established trusted leadership in Canadian and international medical cannabis markets through robust regulatory expertise, investment in technology and distribution, and an unwavering commitment to science. A strict adherence to EU and TGA GMP-certified production enables the company’s success in international markets.
